Cytokinetics

Initial read: evidence-positive, valuation-constrained. ACACIA-HCM gives FDA a clean statistical case in symptomatic non-obstructive HCM, but the trial settles the regulatory question more convincingly than the commercial one.

1. At Week 36, KCCQ-CSS improved by 11.4 points with aficamten versus 8.4 with placebo, a 3.0-point treatment difference, while peak oxygen consumption increased by 0.64 mL/kg/min versus a 0.03 decline, a 0.67 mL/kg/min difference. The 53% versus 13% multi-domain responder analysis makes the totality of benefit more persuasive, but it is a secondary framing around modest absolute primary-endpoint effects and a large placebo response.
2. The obstructive-HCM launch is credible but still early: of $25.3 million in 2Q26 product revenue, $23.0 million was U.S. revenue and $2.3 million reflected initial German distributor purchases; approximately 1,500 patients had been dispensed MYQORZO cumulatively, not necessarily remained on treatment. At $75.20 per share and 139.0 million shares outstanding, the September 11 equity value was approximately $10.45 billion.
3. After June cash and reported borrowings, headline enterprise value was approximately $9.9 billion and moves toward $10.6 billion when reported royalty and revenue-participation liabilities are included. The stock therefore needs meaningful obstructive-HCM share and a commercially relevant non-obstructive-HCM market.
4. That outcome is achievable, but it is being underwritten as the base case rather than offered as inexpensive optionality.